ASH 2024 – J&J reveals more about Lava's secret sauce
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
Kyowa buys into menin, but it's not Syndax's
Syndax scored the first menin approval, but Kura is first with a licensing deal.
Heartache for Syndax
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
ASH 2024 preview – menin inhibitors face off again
Kura will see more combo data, while a new contender from Sumitomo emerges.
Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
